Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Novavax Inc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $43.11, while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| GPTY | NVAX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $11.19 |
52-Week Low | $34.73 | $6.22 |
Market Cap | — | $1.31B |
Enterprise Value | — | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY trades at $43.11, up 1.07% with a bullish technical signal supported by moving averages. The YieldMax AI & Tech Portfolio Option Income ETF demonstrates consistent weekly dividend distributions, with recent payouts ranging from $0.28-$0.37. Technical indicators show strong momentum with RSI at 83.06 suggesting potential overbought conditions, while support and resistance cluster around $42-$43 levels.
The ETF's strategy of harvesting options premiums from AI and semiconductor stocks provides high yield exposure, though the concentrated tech focus and elevated RSI levels warrant caution. Recent analysis highlights GPTY's balance of income generation and capital preservation compared to peers, but dependence on semiconductor momentum presents volatility risks.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
